Rajab A, Axler O, Leung J, Wozniak M, Porwit A
Hematology Department, LifeLabs, Toronto, ON, Canada.
Klinisk patologi, Labmedicin, Medicinsk Service, Region Skåne, Lunds Universitetsjukhus, Lund, Sweden.
Int J Lab Hematol. 2017 May;39 Suppl 1:76-85. doi: 10.1111/ijlh.12678.
We have developed a lymphoproliferative disorder screening tube (LPD-ST) with the aim to provide comprehensive immunophenotyping of lymphocyte subsets with minimal need for additional testing. The LPD-ST consists of CD4/kappa FITC, CD8/lambda PE, CD3/CD14ECD, CD38PC5.5, CD20/CD56PC7, CD10APC, CD19APC-A700, CD5APC-A750, CD57/CD23PB and CD45KO. The LPD-ST was validated against previously used lymphocyte subset panels in Canada (n=60) and in Sweden (n=43) and against the OneFlow LST (n=60). The LPD-ST panel was then implemented in clinical practice using dried monoclonal antibody reagents (Duraclone ) on 649 patient samples in Sweden. In 204 of 649 samples (31%), a monotypic B-cell population was found. Of these cases, a final diagnosis could be rendered in 106 cases (52%), and in the remainder, additional B-cell immunophenotyping was performed. In 20 (3%) samples, an aberrant T-cell population was confirmed by additional testing. Of 425 samples diagnosed as normal/reactive lymphoid tissue, 50 (12%) required additional immunophenotyping, mostly due to an abnormal CD4/CD8 ratio. The LPD-ST tube significantly minimizes the need for additional testing, improves the turn-around time, and reduces the cost of LPD immunophenotyping. It is also suitable for investigating paucicellular samples such as cerebrospinal fluid or fine needle aspirates.
我们研发了一种淋巴细胞增殖性疾病筛查管（LPD-ST），旨在以最少的额外检测需求对淋巴细胞亚群进行全面的免疫表型分析。LPD-ST由CD4/κ异硫氰酸荧光素（FITC）、CD8/λ藻红蛋白（PE）、CD3/CD14藻红蛋白-氰化物（ECD）、CD38藻红蛋白-花青苷5.5（PC5.5）、CD20/CD56藻红蛋白-花青苷7（PC7）、CD10别藻蓝蛋白（APC）、CD19别藻蓝蛋白-A700、CD5别藻蓝蛋白-A750、CD57/CD23藻红蛋白-别藻蓝蛋白（PB）和CD45藻红蛋白-橙红色荧光蛋白（KO）组成。LPD-ST在加拿大（n = 60）和瑞典（n = 43）针对先前使用的淋巴细胞亚群检测板以及针对OneFlow LST（n = 60）进行了验证。然后，LPD-ST检测板在瑞典使用干燥单克隆抗体制剂（Duraclone）对649份患者样本进行临床应用。在649份样本中的204份（31%）中发现了单克隆B细胞群体。在这些病例中，106例（52%）能够做出最终诊断，其余病例则进行了额外的B细胞免疫表型分析。在20份（3%）样本中，额外检测确认存在异常T细胞群体。在425份被诊断为正常/反应性淋巴组织的样本中，50份（12%）需要进行额外的免疫表型分析，主要是由于CD4/CD8比值异常。LPD-ST管显著减少了额外检测的需求，缩短了周转时间，并降低了LPD免疫表型分析的成本。它也适用于研究细胞数量少的样本，如脑脊液或细针穿刺抽吸物。
